1商品名Brovana2开发与上市厂商本品由美国Sepracor公司研制开发,2006年10月获FDA批准,并于2007年4月首先在美国上市。3适应证本品适用于慢性阻塞性肺疾病(COPD)患者支气管收缩的长期维持治疗,包括慢性支气管炎和肺气肿。4药理本品为一种选择性长效b2受体激动剂,可激活 1 Trade name Brovana2 development and listing of manufacturers This product developed by the United States Sepracor company, in October 2006 by the FDA approved and in April 2007 the first listing in the United States. 3 Indications This product is suitable for long-term maintenance of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. 4 pharmacology This product is a selective long-acting b2 receptor agonist, can be activated